Alkegen Battery Group Will Exhibit at AABC Europe in Mainz, and The Battery Show in Stuttgart, Germany this June
8.6.2022 20:50:00 EEST | Business Wire | Press release
Alkegen, a leading specialty materials platform creating transformational battery materials, today announced they will be exhibiting at the upcoming AABC Europe Conference in Mainz, and The Battery Show Europe in Stuttgart, Germany. Alkegen’s Battery Group focuses on delivering battery innovation with advanced materials for Lithium Ion Battery (LiB) thermal barriers and electrical protection, battery separator technology, and revolutionary silicon fiber anode battery material (SiFAB®) that enables greater energy density, faster charges, and longer battery life in electric vehicles, portable electronics and energy storage systems. Alkegen, formerly Unifrax and Lydall, is a one-of-a-kind specialty materials platform dedicated to human health and sustainability.
The technical capabilities of the Alkegen Battery Group support customer partnerships with a global engineering team, deep technical expertise, and customer collaboration. These unique capabilities allow for a globally coordinated team of engineers and designers with a dedicated presence in each region, solutions designed for easy installation and handling, and scalable, customized solutions that meet budgets and optimize performance.
Alkegen’s range of technical capabilities includes Design, Testing, Prototyping and Serial Production. The global design team employs 3D modelling software to collaborate with customers and optimize form, fit and function. Thermal, mechanical, environmental and compression testing are used for part validation and new product development. The engineering team prototypes both in-pack and in-cell solutions once designed to validate product functionality. Finally, Alkegen’s global footprint of IATF certified sites and engineering teams support scale up through regional production locations in Europe, North America and the Asia-Pacific region.
Alkegen’s transformational battery portfolio includes both in-cell and in-pack solutions. In-cell solutions such as separators and additives to improve cell performance and safety include SiFAB, Alkegen’s fibrous silicon anode battery material with ultra-high capacity that enables greater energy density and is highly scalable. SiFAB technology was launched last year and will scale to production this summer. Also from Alkegen, Inovion™ is a high surface area fibrous separator paper that promotes rapid ion exchange. Alkegen also offers several in-pack solutions including high-temperature lightweight products designed to reduce thermal runaway propagation along with providing mechanical, electrical and thermal protections within the battery pack. Innovative product solutions also include FyreBlocker™ LiB, AlkeGel™ Aerogel Materials and FyreWrap® LiB performance materials. These in-cell and in-pack innovations have valuable functions in numerous industries and applications from portable electronics, e-mobility, to robotics.
”Alkegen’s Battery Group is focused on delivering the latest battery technologies and developments from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Adam Kelsall, General Manager, Alkegen Battery Group. “This transformational portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium-ion battery fire protection, creating greater battery energy density and delivering longer battery life in both electric vehicles and consumer electronics,” said Kelsall.
Alkegen will be available to discuss these innovative new battery materials and more during the 2022 AABC Europe Show June 13-15, in Mainz, and The Battery Show June 28-30, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com.
About Alkegen
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen is vertically integrated across multiple process technology platforms designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608006046/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development17.2.2026 16:10:00 EET | Press release
Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/ Michael Clay, Caidya's Chief Operating Officer Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust. Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remains the best approach for most decision problems—as demonstrated by thousands of successful customer implementatio
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 15:00:00 EET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 15:00:00 EET | Press release
Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Esri’s geospatial platform. Field teams use the PIX4Dcatch app with real-time kinematics (RTK) devices to scan trenches and infrastructure. The generated high precision georeferenced records can now be published into Esri’s ArcGIS Online. Scans become 3D models and point clouds, viewable as a Scene Layer. Existing data can also be visualized in augmented reality for instant “as-designed” versus “as-built” verification before closing trenches. “We are focused on turning hidden infrastructure into functional data,” said Andrey Kleymenov, CEO of Pix4D. “By connecting PIX4Dcatch with a compatible RTK device to the Esri ecosystem, we are enab
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom